Dr. David Bulmer

Biography

David Bulmer studied pharmacology at the University of Manchester and obtained a PhD in physiology focusing on central processing of sensory input from the heart under the supervision of Professor Mike Spyer at University College London. He then completed post-doctoral training with Professor David Grundy, focusing on sensory function in the gastrointestinal tract at the University of Sheffield. Following this, David joined the Neuroscience and Gastrointestinal Centre of Excellence in Drug Discovery (CEDD) at GlaxoSmithKline, where he led a translational research group in immuno-inflammation. In 2009, he joined Queen Mary University of London (QMUL) as a lecturer in Neurogastroenterology with funding from the Medical Research Council's Skills Gap Award, establishing a world-class translational neuroscience group using human tissue to study the mechanisms of sensory signaling in gut health and disease. His research has notably included groundbreaking recordings from human visceral nociceptors and the characterization of their mechanisms. In July 2017, David joined the Department of Pharmacology at the University of Cambridge, rapidly setting up a translational human tissue laboratory. His research primarily focuses on abdominal pain as a leading cause of morbidity in gastrointestinal disease, particularly in functional gastrointestinal disorders like irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). He investigates the critical roles of various mediators and mechanisms in peripheral sensitization and aims to develop effective visceral analgesics for treating pain associated with IBS and IBD.

Research Interests

Experience